| Literature DB >> 36118645 |
Igor Sljivic1, Roberto Trasolini2, Fergal Donnellan3.
Abstract
Background and study aims Single-operator peroral cholangioscopy (SOC) is a therapeutic modality for difficult biliary stone disease. Given its high success rate and increasing availability, analysis of the economic impact of early SOC utilization is critical for clinical decision-making. Our aim is to compare the cost-effectiveness of different first and second-line endoscopic modalities for difficult-to-treat choledocholithiasis. Patients and methods A decision-tree model with a 1-year time horizon and a hypothetical cohort of 200 patients was used to analyze the cost-effectiveness of SOC for first, second and third-line intervention in presumed difficult biliary stones. We adopted the perspective of a Canadian tertiary hospital, omitting recurrence rates associated with endoscopic retrograde cholangiopancreatography (ERCP). Effectiveness estimates were obtained from updated meta-analyses. One-way sensitivity analyses and probabilistic sensitivity analyses were also performed to assess how changes in key parameters affected model conclusions. Results First- and second-line SOC achieved comparable clinical efficacy from 96.3 % to 97. 6 % stone clearance. The least expensive strategy is third-line SOC (SOC-3: $800,936). Performing SOC during the second ERCP was marginally more expensive (SOC-2: $ 816,584) but 9 % more effective. The strategy of first-line SOC incurred the highest hospital expenditures (SOC-1: $ 851,457) but decreased total procedures performed by 16.9 % when compared with SOC-2. Sensitivity analysis was robust in showing SOC-2 as the most optimal approach. Conclusions Second-line SOC was superior to first and third-line SOC for treatment of difficult biliary stones. When based on meta-analysis of non-heterogeneous trials, SOC-2 is more cost-effective and cost-efficient. Our study warrants a larger pragmatic effectiveness trial. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).Entities:
Year: 2022 PMID: 36118645 PMCID: PMC9473834 DOI: 10.1055/a-1873-0884
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1Management model for treating difficult biliary stones. SOC, peroral cholangioscopy; ERCP, endoscopic retrograde cholangioscopy. M1 indicates a decision to use ERCP. M2 indicates a decision to use SOC. SOC-1 – SOC used as initial step. SOC-2 – SOC delayed until after ERCP failure. SOC-3 – SOC delayed until two failed ERCP attempts.
Cost data used in the model.
|
|
|
| |
|
|
| ||
|
| |||
| RN pre-op | 43.24 /h | 11 min | 11 min |
| RN intra-op | 43.24 /h | 47 min | 47 min |
| RN post-op | 43.24 /h | 16 min | 16 min |
| Tech intra-op | 37.68 /h | 47 min | 47 min |
| Porter/ward aid | 21.25 /h | 20.5 min | 20.5 min |
| SPD technician | 22.70 /h | 80 min | 80 min |
| Booking clerk/admitting clerk | 21.25 /h | 31 min | 31 min |
| HR chart management | 18.16 /h | 20 min | 20 min |
| HR transcription | 27.38 /h | 12 min | 12 min |
| HR abstracting + coding | 32.41 /h | 15 min | 15 min |
| Nursing relief | 20 % of totals | – | – |
| Staff benefits | 24.9 % of totals | – | – |
| Leadership cost | 5 % of totals | – | – |
| Hospital bed | 3700 /night | – | – |
|
| |||
| Basic ERCP prep supplies | 170.23 | 1.0 | 1.0 |
| Sphinctertome | 218.13 | 1.0 | 1.0 |
| Wires + guidewires | 93.55 | 1.2 | 1.2 |
|
Stent delivery system
| 150.00 | 1.0 | 1.0 |
|
Plastic Stent
| 69.44 | 1.0 | 1.0 |
|
Rat tooth stent retriever
| 45.01 | 1.0 | 1.0 |
| Basket | 250.52 | 1.0 | 0 |
| CRE balloon | 120.62 | 1.0 | 0 |
| Dilation balloon | 151.19 | 1.0 | 0 |
| Balloon inflation kit | 75.00 | 1.0 | 0 |
| 50cc OMNI dye | 9.75 | 1.0 | 0 |
| SpyGlass catheter | 1695 | 0 | 1.0 |
| EHL probe | 395 | 0 | 1.0 |
| Equipment repairs/case | 16.42 | 1.0 | 1.0 |
| Infrastructure + OH/case | 15 % of totals | – | – |
|
| |||
| ERCP – Stone extraction | 526.12 | 1.0 | 1.0 |
| Visit – office, Gastroenterology | 62.25 | 0.5 | 0.5 |
| Visit – hospital, Gastroenterology | 40.65 | 0.5 | 0.5 |
| Anesthesia for ERCP/SOC | 100.25 | 1.0 | 1.0 |
| Anesthesia consultation | 119.56 | 1.0 | 1.0 |
|
|
|
| |
HR, human resources; OH, overhead; ERCP, endoscopic retrograde cholangioscopy; SOC, single-operator peroral cholangioscopy.
The costs of stenting equipment and future stent removal were only included in calculating the cost of failed procedures.
Fig. 2Tornado Diagram: incremental cost-effectiveness ratio (ICER) (SOC-3 vs SOC-2). Baseline model ICER is set at $ 2500/case. Secondary ERCP refers to ERCP procedures after an already failed ERCP ± SOC-EHL. Cost of ERCP and cost of SOC refer to the equipment costs.
Results of economic analysis.
|
|
|
|
|
|
|
|
|
| SOC-3 | 800,936 | 2697 | 0.885 | 3047 | |||
| SOC-2 | 816,584 | 2933 | 236 | 0.978 | 0.093 | 2998 | 2537 |
| SOC-1 | 851,457 | 3679 | 982 | 0.963 | 0.078 | 3820 | 12590 |
SOC, peroral cholangioscopy. All costs are expressed in 2018 $Cdn.
SOC-3 and SOC-2 are undominated. SOC-1 is absolutely dominated.
Effectiveness is described as procedural success rate.
Findings underscored by one-way sensitivity analysis.
|
|
|
|
| ||
| Cost of SOC-EHL equipment | 2987 | 3286 | POC-2 is optimal | 2688 | POC-2 is dominant |
| Cost of ERCP equipment | 1705 | 1875 | POC-2 is dominant | 1534 | POC-2 is optimal |
| Success rate of SOC-EHL | 0.88 | 0.98 | POC-2 is dominant | 0.78 | POC-3 is dominant |
| Success rate of conventional ERCP after first failure of ERCP ± SOC | 0.69 | 0.79 | POC-3 is optimal | 0.59 | POC-2 is dominant |
| Success rate of initial conventional ERCP | 0.63 | 0.73 | POC-2 is optimal | 0.53 | POC-2 is optimal |
SOC, peroral cholangioscopy. All costs are expressed in 2018 $Cdn.
The use of the term dominant is reserved for scenarios in which SOC-2 or –3’s Incremental Cost-Effectiveness Ratio (ICER) is less expensive than its baseline model’s ICER.